US Stock MarketDetailed Quotes

AUTL Autolus Therapeutics

Watchlist
  • 1.730
  • -0.020-1.14%
Close Feb 28 16:00 ET
  • 1.760
  • +0.030+1.73%
Post 20:01 ET
460.39MMarket Cap-1.42P/E (TTM)

About Autolus Therapeutics Company

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Company Profile

SymbolAUTL
Company NameAutolus Therapeutics
Listing DateJun 22, 2018
Issue Price17.00
Founded2018
CEODr. Christian Itin, PhD.
MarketNASDAQ
Employees471
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressThe Mediaworks,191 Wood Lane,White City
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW12 7FP
Phone44-20-3829-6230
Websitehttp://www.autolus.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Christian Itin, PhD.
  • Chief Executive Officer and Director
  • 1.92M
  • Martin Pule
  • Senior Vice President and Chief Scientific Officer
  • --
  • Christopher Vann
  • Senior Vice President and Chief Operating Officer
  • --
  • Dr. Edgar Braendle
  • Senior Vice President and Chief Development Officer
  • --
  • Robert F. Dolski
  • Senior Vice President, Chief Financial Officer
  • --
  • Dr. Christopher Willia PhD
  • Senior Vice President and Chief Business Development Officer
  • --
  • Alexander Swan
  • Senior Vice President, Chief Human Resources Officer
  • --
  • Brent Rice
  • Senior Vice President and Chief Commercial Officer
  • --
  • David Brochu
  • Senior Vice President and Chief Technical Officer
  • --
  • Michael W. Bonney
  • Chairman of the Board
  • --
  • Robert W. Azelby
  • Director
  • --
  • Dr. Ravi Madduri Rao
  • Director
  • --
  • Dr. Elisabeth Leiderman, M.D.
  • Director
  • 12.73K
  • Dr. Joseph Anderson, PhD.
  • Independent Director
  • 195.65K
  • John E. Berriman
  • Independent Director
  • 163.15K
  • Dr. Robert Iannone, M.D.
  • Independent Director
  • 134.86K
  • Cynthia M. Butitta
  • Independent Director
  • 164.65K
  • William D. Young
  • Independent Director
  • 175.82K
  • Dr. Martin Murphy, PhD
  • Independent Director
  • 158.28K
  • Linda C. Bain
  • Independent Director
  • 169.52K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Strategy
MSTR
+6.41%
MARA Holdings
MARA
+6.02%
Tesla
TSLA
+3.91%
Coinbase
COIN
+3.48%
Apple
AAPL
+1.91%

Unlock the Full List